These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 33752685)

  • 21. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
    Foeldvari I; Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
    Beukelman T; Ringold S; Davis TE; DeWitt EM; Pelajo CF; Weiss PF; Kimura Y;
    J Rheumatol; 2012 Sep; 39(9):1867-74. PubMed ID: 22859354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.
    Kearsley-Fleet L; Sampath S; McCann LJ; Baildam E; Beresford MW; Davies R; De Cock D; Foster HE; Southwood TR; Thomson W; Hyrich KL
    Rheumatology (Oxford); 2019 Feb; 58(2):331-335. PubMed ID: 30358861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
    Atemnkeng Ntam V; Klein A; Horneff G
    Expert Opin Drug Saf; 2021 Jan; 20(1):93-100. PubMed ID: 33148061
    [No Abstract]   [Full Text] [Related]  

  • 26. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
    Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
    Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis.
    Ravelli A; Viola S; Migliavacca D; Ruperto N; Pistorio A; Martini A
    J Pediatr; 1999 Sep; 135(3):316-20. PubMed ID: 10484796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis.
    Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier G; Verazza S; Giancane G; Consolaro A; Ravelli A
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):50. PubMed ID: 31345226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score.
    Horneff G; Becker I
    Rheumatology (Oxford); 2014 Jul; 53(7):1229-34. PubMed ID: 24599918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and validation of a composite disease activity score for juvenile idiopathic arthritis.
    Consolaro A; Ruperto N; Bazso A; Pistorio A; Magni-Manzoni S; Filocamo G; Malattia C; Viola S; Martini A; Ravelli A;
    Arthritis Rheum; 2009 May; 61(5):658-66. PubMed ID: 19405003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis.
    Horneff G; Klein A; Ganser G; Sailer-Höck M; Günther A; Foeldvari I; Weller-Heinemann F
    Pediatr Rheumatol Online J; 2017 Nov; 15(1):78. PubMed ID: 29116003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Windschall D; Horneff G
    Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
    Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
    Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Kröger L; Aalto K; Lahdenne P
    Pediatr Rheumatol Online J; 2019 Dec; 17(1):80. PubMed ID: 31842940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis.
    Alcântara AC; Leite CA; Leite AC; Sidrim JJ; Silva FS; Rocha FA
    J Rheumatol; 2014 Feb; 41(2):338-44. PubMed ID: 24334641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
    Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids.
    Brik R; Gepstein V; Berkovitz D
    Clin Rheumatol; 2005 Nov; 24(6):612-4. PubMed ID: 15877178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases.
    Yamazaki S; Shimbo A; Akutsu Y; Takase H; Morio T; Mori M
    Pediatr Rheumatol Online J; 2020 Mar; 18(1):26. PubMed ID: 32293465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.